Description

TT-232, also known as CAP-232 or TLN-232, is a cyclic peptide analog of somatostatin engineered to selectively activate sst-1 and sst-4 receptors. It exhibits potent anti-proliferative activity, inducing apoptosis in tumor cell models such as colon and pancreatic cancers. Unlike classical somatostatin analogs, TT-232 avoids systemic endocrine effects and targets intracellular signaling to modulate cell behavior. Produced under GMP standards with high purity (?98.27%), TT-232 is ideal for oncology research, signal-transduction studies, and inflammation models. For laboratory research use only.

Product Specifications

Mechanism of Action & Research Applications

TT-232 functions as a somatostatin-like analogue that selectively targets sst-1 and sst-4 receptors, modulating intracellular signaling pathways to inhibit cell proliferation and trigger apoptosis—particularly in colon and pancreatic tumor models. It operates via “signal-transduction therapy,” altering cellular communication without disrupting basal functions, and has demonstrated anti-inflammatory effects in experimental models. Ideal for research in oncology, receptor pharmacology, and cellular signaling. For laboratory research use only.

Side Effects (For Reference Only in Models)

In experimental models, TT-232 has shown selective tumor cell apoptosis and anti-proliferative effects without impacting systemic hormone release. Some signaling assays report modulation of enzyme activity in tumor cell lines. These findings are context-specific and intended for experimental design only. For laboratory research use only.

Disclaimer

TT-232 is intended strictly for laboratory research use only. It is not approved for human or veterinary use. All handling should follow institutional laboratory safety protocols.